Total Payments
$571,087
2024 Payments
$61,570
Companies
29
Transactions
990
Medicare Patients
3,437
Medicare Billing
$679,625
Payment Breakdown by Category
Other$483,760 (84.7%)
Travel$52,845 (9.3%)
Food & Beverage$23,115 (4.0%)
Consulting$11,155 (2.0%)
Education$212.48 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $483,760 | 181 | 84.7% |
| Travel and Lodging | $52,845 | 235 | 9.3% |
| Food and Beverage | $23,115 | 563 | 4.0% |
| Consulting Fee | $11,155 | 4 | 2.0% |
| Education | $212.48 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $442,658 | 493 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $81,998 | 201 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $28,218 | 81 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,625 | 68 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $584.71 | 20 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $481.54 | 16 | $0 (2024) |
| Genentech USA, Inc. | $425.79 | 13 | $0 (2022) |
| Grifols USA, LLC | $394.41 | 18 | $0 (2023) |
| GENZYME CORPORATION | $292.53 | 14 | $0 (2024) |
| Mylan Specialty L.P. | $248.43 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,570 | 91 | GlaxoSmithKline, LLC. ($60,906) |
| 2023 | $112,445 | 144 | GlaxoSmithKline, LLC. ($111,835) |
| 2022 | $57,239 | 90 | GlaxoSmithKline, LLC. ($56,201) |
| 2021 | $66,108 | 110 | GlaxoSmithKline, LLC. ($65,190) |
| 2020 | $46,248 | 69 | GlaxoSmithKline, LLC. ($45,786) |
| 2019 | $113,877 | 194 | GlaxoSmithKline, LLC. ($97,135) |
| 2018 | $47,995 | 150 | AstraZeneca Pharmaceuticals LP ($27,899) |
| 2017 | $65,606 | 142 | AstraZeneca Pharmaceuticals LP ($50,241) |
All Payment Transactions
990 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/30/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $107.08 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: RESPIRATORY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $96.66 | General |
| Category: RESPIRATORY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | Cash or cash equivalent | $16.36 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $66.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $1,070.08 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $124.71 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $951.32 | General |
| Category: RESPIRATORY | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $1,296.45 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $168.48 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $111.73 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $891.76 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $61.44 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 630 | 1,232 | $350,585 | $156,469 |
| 2022 | 18 | 896 | 1,475 | $348,950 | $177,954 |
| 2021 | 20 | 1,018 | 1,619 | $373,620 | $188,605 |
| 2020 | 18 | 893 | 1,441 | $308,820 | $156,597 |
Total Patients
3,437
Total Services
5,767
Medicare Billing
$679,625
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 147 | 487 | $170,450 | $95,635 | 56.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 139 | 313 | $46,950 | $22,445 | 47.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 77 | 89 | $26,700 | $13,394 | 50.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 70 | $10,500 | $7,604 | 72.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 45 | $25,540 | $4,764 | 18.7% |
| 94003 | Follow-up inpatient or observation ventilation assistance and management | Facility | 2023 | 11 | 51 | $5,100 | $2,977 | 58.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 38 | $15,040 | $2,697 | 17.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 16 | $12,925 | $2,643 | 20.5% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 47 | 54 | $16,840 | $1,337 | 7.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 16 | 16 | $3,480 | $862.68 | 24.8% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Facility | 2023 | 21 | 21 | $8,400 | $815.85 | 9.7% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 16 | 16 | $3,830 | $779.40 | 20.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 16 | 16 | $4,830 | $513.80 | 10.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 140 | 469 | $164,150 | $96,122 | 58.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 119 | 239 | $35,850 | $15,630 | 43.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 78 | 87 | $26,100 | $15,427 | 59.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 95 | $21,375 | $10,797 | 50.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 103 | $20,600 | $7,789 | 37.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 26 | 38 | $9,500 | $6,518 | 68.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 48 | $7,200 | $4,561 | 63.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $5,100 | $3,585 | 70.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 56 | 60 | $9,000 | $3,447 | 38.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 56 | 60 | $12,000 | $3,166 | 26.4% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2022 | 34 | 36 | $14,400 | $2,970 | 20.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 58 | 64 | $9,600 | $2,402 | 25.0% |
About Dr. Michael Mandel, MD
Dr. Michael Mandel, MD is a Pulmonary Disease healthcare provider based in Larchmont, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861463564.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mandel, MD has received a total of $571,087 in payments from pharmaceutical and medical device companies, with $61,570 received in 2024. These payments were reported across 990 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($483,760).
As a Medicare-enrolled provider, Mandel has provided services to 3,437 Medicare beneficiaries, totaling 5,767 services with total Medicare billing of $679,625. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Larchmont, NY
- Active Since 01/30/2006
- Last Updated 02/22/2013
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1861463564
Products in Payments
- NUCALA (Biological) $236,293
- TRELEGY ELLIPTA (Drug) $88,630
- AREXVY (Drug) $73,273
- BEVESPI AEROSPHERE (Drug) $71,334
- LONHALA MAGNAIR (Drug) $14,011
- UTIBRON (Drug) $11,538
- SPIRIVA RESPIMAT (Drug) $10,936
- SYMBICORT (Drug) $8,316
- ANORO (Drug) $4,766
- ANORO ELLIPTA (Drug) $4,230
- Utibron (Drug) $1,910
- DALIRESP (Drug) $1,186
- DUPIXENT (Biological) $757.98
- OFEV (Drug) $605.56
- OPSUMIT (Drug) $410.68
- FASENRA (Biological) $372.72
- Xolair (Biological) $333.92
- STIOLTO RESPIMAT (Drug) $304.24
- Prolastin-C Liquid (Biological) $222.88
- FASENRA (Drug) $207.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.